CNS Pharmaceuticals, Inc. (CNSP)

USD 0.11

(0.0%)

Market Cap (In USD)

6.43 Million

Revenue (In USD)

-

Net Income (In USD)

-18.85 Million

Avg. Volume

5.54 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.096-70.0
PE
-
EPS
-
Beta Value
1.049
ISIN
US18978H2013
CUSIP
18978H102
CIK
1729427
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. John Michael Climaco Esq., J.D.
Employee Count
-
Website
https://www.cnspharma.com
Ipo Date
2019-11-08
Details
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.